Answer the most difficult questions in cancer
Oncology biomarker research is about translating progress made in identifying relevant biomarkers in basic research into cancer therapeutics that potentially benefit patients. Our approach uses mass spectrometry as the discovery engine to discover new oncogenic or tumorgenic biomarkers. Cancer research techniques using mass spectrometry can be used to discover and validate biomarkers that can be used for early detection of cancer, proteomics in cancer prognostics, proteogenomics and monitoring response to therapy.
The versatile nature of mass spectrometry gives cancer researchers the flexibility in using any type of clinical sample including cell lines, tumor tissue, serum, plasma, urine, saliva, NAF for breast cancer.
Unless otherwise noted, all products are for research use only, not for use in diagnostic procedures.
Cancer biomarker research
With access to our innovative products and platforms, you can answer all the leading questions one would face when performing cancer research.
Bringing together the worlds of biology and chemistry with new technologies
Advances in mass spectrometry and separation science are bringing genome-scale proteomic analyses within our reach. Thomas Conrads, Associate Director of Scientific Technologies in the Inova Schar Cancer Institute, describes how his lab applies the power of proteomic tools to help women with cancer.
Webinars
Translating Proteomics into Clinical Diagnostics
Dr. Eleftherios P. Diamandis, MD, PhD, FRCP(C) with Mount Sinai Hospital, Dept. of Pathology & Laboratory Medicine & the Lunefel-Tanenbaum Research Institute, discusses his approach to using LCMS technology to identify potential biomarkers and how it may apply utility
in the future of clinical diagnostics.
Detection of Pathogen Induced Cancer in a Human T-Cell Leukemia Virus Type 1 Disease Model on LC-HRAM Platform
Dr. Sucharita Dutta, Senior Research Associate at the Eastern Virginia Medical School discusses the Human T-Cell Leukemia Virus Type 1 (HTLV-1) as the potential factor for the development of an aggressive lymphoma, Adult T-cell Leukemia (ATL).
 |  |  |  |  |  |
| Andrew Hoofnagle | Bruno Domon | Carol Nilsson | Daniel Chan | Tom Conrads | Eleftherios Diamandis |
Integrating Proteomics and Genomics to Unlock Biological Function
Learn how a proteogenomics approach can improve your investigational power.
Dr. Eleftherios Diamandis talks about using multiple technologies to better understand cancer
Learn how this technology compliments genomic analysis in clinical & translational research laboratories.
